Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia
NCT04051996 · Yale University · PHASE2 · terminated · last registry update 2021-10-15 · Acute myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Unable to accrue patients following COVID-19 study pause.” | Open Targets' class: covid19 | Registry record, Yale University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SMO in acute myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-07-01Also stopped (terminated): University Hospital Heidelberg, Gemtuzumab Ozogamicin 147 + Gemtuzumab Ozogamicin 1 (NCT04093505)
- 2022-06-09Also stopped (withdrawn): City of Hope Medical Center, Bosutinib Monohydrate + Decitabine (NCT04655391)
- 2022-03-18Results posted on the registry: Pfizer, PF-04449913 + PF-04449913 (NCT02038777)
- 2022-01-25Results posted on the registry: University of Colorado, Denver, PF-04449913 (NCT01841333)
- 2021-04-13Phase 3 first posted: Pfizer, Glasdegib + Azacitidine (NCT04842604)
- 2021-03-05Results posted on the registry: Pfizer, PF-04449913 (Glasdegib) + Azacitidine (NCT02367456)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision